Yangtze River Pharmaceutical will market eight Alvotech biosimilars in China, under the terms of an exclusive deal that has just been agreed with the Alvogen sister company. The agreement involves the Alvotech & CCHT Biopharmaceutical joint venture between Alvotech and Changchun High & New Technology Industries – founded in March 2019 – and provides for biosimilar candidates to be manufactured in a new Chinese facility being constructed in Changchun.
“Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient...





